Drugs / Glulisine Insulin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT00640991 | Apr 2008 → Jun 2010 | hyperglycemia, myocardial infarction | Population Health Research Institute | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT03013985 Background | May 2017 → Mar 2019 | type 2 diabetes mellitus | Emory University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Glulisine Insulin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03013985 ↗ |
| Modality | Protein / enzyme biologic | “Glulisine is a mealtime insulin taken either 15 minutes before or 20 minutes after a meal.” NCT03013985 ↗ |
| Route | Intravenous | “IV infusion of glulisine” NCT00640991 ↗ |